Join the Oncology Voice Network. Join for Free
Skip Level Meetings: Prepare, Purpose, Pitfalls
Skip Level Meetings Medical Science Liaison Paul Ward BeiGene Medical Affairs Xcellence Summit Momentum Events

Skip Level Meetings: Prepare, Purpose, Pitfalls


Share This Article


Summary

In this episode, Paul Ward, head of field medical at BeiGene, joins Tom Caravela to delve into the concept of skip level meetings. Paul shares insights on who should initiate these meetings and their objectives, emphasizing the importance of effective communication. The discussion covers preparation strategies for MSLs, potential benefits for leaders, and advice on avoiding common pitfalls. Paul also provides guidance on making a positive impression in informal settings and navigating group dynamics. The episode wraps up with practical advice for both MSLs and leaders, alongside a mention of Momentum Events and a discount code.

My guest today is Paul Ward, Head of Field Medical Oncology and Hematology at BeiGene and MSL Society Advisory Board Member and we discuss the pros and cons of “Skip Level” meetings.

This episode is sponsored by Momentum Events and their upcoming Medical Affairs Xcellence Summit, October 13-14 in Philadelphia. For more details, visit: https://bit.ly/3zFol58 and use discount code TOM20 to get a 20% discount on your registration! Early Bird Registration expires on August 26th.

Paul shares…

πŸ‘‰ What the term “Skip Level Meeting” means
πŸ‘‰ Who initiates these meetings
πŸ‘‰ What the goal or purpose of these meetings is
πŸ‘‰ What preparation is involved for both the leaders and the MSLs
πŸ‘‰ What positives come from these meetings
πŸ‘‰ What the dangers are that can result from these meetings
πŸ‘‰ Advice for MSLs and employees who participate in the meetings

Click for Source
Skip Level Meetings, Medical Science Liaison, Paul Ward BeiGene, Medical Affairs Xcellence Summit, Momentum Events

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Podcast
Social Media Listening Evolved
Partner Avatar MSL Talk: Tom Caravela, Conor McGladrigan, Kevin Peterson

Social Media Listening Evolved

Podcast
Over-Negotiation-How to Botch a Job Offer
Partner Avatar MSL Talk: Tom Caravela

Over-Negotiation-How to Botch a Job Offer

Article
Median Survival or Mean Survival: Which Measure Is the Most Appropriate for Patients, Physicians, and Policymakers?
OVN Avatar Omer Ben‐Aharon, Racheli Magnezi, Moshe Leshno, and Daniel A. Goldstein

Median Survival or Mean Survival: Which Measure Is the Most Appropriate for Patients, Physicians, and Policymakers?

Press Release
Announcing the Launch of Voices of Oncology: A Landmark Collaboration with Forbes
OVN Avatar OVN Staff

Announcing the Launch of Voices of Oncology: A Landmark Collaboration with Forbes

Press Release
Introducing OncologyVoiceNetwork.com
OVN Avatar OVN Staff

Introducing OncologyVoiceNetwork.com

Article
Updated estimates of eligibility for and response to genome-targeted oncology drugs among US cancer patients, 2006-2020
OVN Avatar A. Haslam, M.S. Kim, V. Prasad

Updated estimates of eligibility for and response to genome-targeted oncology drugs among US cancer patients, 2006-2020

Explore OVN